Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Novo Nordisk Selects Emerson to Help Bring Medication to Market More Quickly to Address Growing Diabetes Epidemic

Emerson
Posted on: 13 Nov 17

Global healthcare company Novo Nordisk has awarded Emerson (NYSE: EMR) a $40 million automation systems and services contract for a new U.S.-based drug manufacturing facility to help battle the global diabetes epidemic. The largest project in its history, Novo Nordisk’s new $2 billion plant in Clayton, N.C., will leverage Emerson’s Project Certainty methodologies and automation technologies to help ensure the plant meets its operational target of 2020.

The new 825,000-square-foot production facility will help the Danish drug company increase manufacturing capacity and meet its goal of doubling production of diabetes drugs over the next decade. According to the Centers for Disease Control and Prevention, more than 29 million Americans are living with diabetes, with another 86 million living with prediabetes.

“Our extensive experience in the life sciences industry and integrated offering for capital projects and automation perfectly positions us to help Novo Nordisk deliver its largest project in history,” said Mike Train, executive president, Emerson Automation Solutions. “Together we can design and deliver this world-class manufacturing facility to be ready on time, and to quickly bring these important diabetes medicines to patients.”

Novo Nordisk will implement elements of Emerson’s Project Certainty approach to help reduce project complexity and achieve the tight project schedule. This transformational approach leverages automation technology, which serves as a central nervous system in a plant, and new methodologies, to reduce costs and complexity and accommodate late-stage project changes.

Novo Nordisk selected Emerson’s integrated portfolio of automation technologies and services, including its DeltaV™ distributed control system (DCS) and Syncade manufacturing execution system (MES). Emerson will also provide smart automation technologies including valves and measurement instrumentation.

For more information about Emerson’s life sciences capabilities, go to www.emerson.com/lifesciences

For more information on Emerson’s Project Certainty methodologies, go to www.emerson.com/project-certainty

About Emerson

Emerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and engineering company providing innovative solutions for customers in industrial, commercial, and residential markets. Our Emerson Automation Solutions business helps process, hybrid, and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. Our Emerson Commercial and Residential Solutions business helps ensure human comfort and health, protect food quality and safety, advance energy efficiency, and create sustainable infrastructure. For more information visit Emerson.com.

Additional resources:

View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005136/en/

Business Wire
www.businesswire.com

Last updated on: 13/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.